MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Home・Lista de Ações・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Fechado

SetorSaúde

32.45 0.81

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

32.05

Máximo

32.73

Indicadores-chave
By Trading Economics
Rendimento	-14M -81M
Vendas	75K 75K
EPS	-1.22
Margem de lucro	-108,422.667
Funcionários	198
EBITDA	-7.8M -81M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+67.23% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	472M 2.1B
Abertura anterior	31.64
Fecho anterior	32.45

Sentimento de Notícias

By Acuity

100%

330 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

18.91 / 20.63 Suporte e Resistência

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de abr. de 2026, 23:25 UTC

Notícias Principais

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 de abr. de 2026, 22:45 UTC

Notícias Principais

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 de abr. de 2026, 18:03 UTC

Ganhos

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 de abr. de 2026, 23:58 UTC

Ganhos

Review & Preview: Earnings Time -- Barrons.com

13 de abr. de 2026, 23:49 UTC

Conversa de Mercado

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 de abr. de 2026, 23:33 UTC

Conversa de Mercado

Notícias Principais

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 de abr. de 2026, 23:20 UTC

Conversa de Mercado

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 de abr. de 2026, 23:01 UTC

Ganhos

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 de abr. de 2026, 23:01 UTC

Ganhos

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 de abr. de 2026, 23:01 UTC

Ganhos

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 de abr. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 de abr. de 2026, 21:53 UTC

Ganhos

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 de abr. de 2026, 21:53 UTC

Ganhos

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 de abr. de 2026, 21:53 UTC

Ganhos

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 de abr. de 2026, 21:53 UTC

Ganhos

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 de abr. de 2026, 21:26 UTC

Notícias Principais

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 de abr. de 2026, 21:23 UTC

Ganhos

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 de abr. de 2026, 21:16 UTC

Ganhos

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Notícias Principais

Basic Materials Roundup: Market Talk

13 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

13 de abr. de 2026, 20:34 UTC

Ganhos

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 de abr. de 2026, 20:34 UTC

Ganhos

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 de abr. de 2026, 20:34 UTC

Ganhos

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 de abr. de 2026, 19:59 UTC

Conversa de Mercado

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 de abr. de 2026, 19:50 UTC

Conversa de Mercado

Notícias Principais

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 de abr. de 2026, 19:27 UTC

Conversa de Mercado

Notícias Principais

Correction to Precious Metals Market Talk on April 9

13 de abr. de 2026, 19:14 UTC

Conversa de Mercado

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 de abr. de 2026, 18:59 UTC

Conversa de Mercado

Notícias Principais

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 de abr. de 2026, 18:59 UTC

Conversa de Mercado

Notícias Principais

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 de abr. de 2026, 18:43 UTC

Conversa de Mercado

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

67.23% parte superior

Previsão para 12 meses

Média 54.5 USD 67.23%

Máximo 90 USD

Mínimo 24 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Recent bullish events outweigh bearish events.

All events are bearish.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.